A novel drug molecule could potentially lead to new treatments to prevent Parkinson’s disease in younger patients, according to new research.
“We are excited about this drug compound because we might have the possibility to develop the first cure for Parkinson’s disease, at least for a subset of patients,” said lead author Kalle Gehring, a Professor in the Department of Biochemistry at McGill University and Canada Research Chair in Structural Studies of Neurodegenerative Diseases.